Stage III Rectal Cancer AJCC v8
Quiénes somos
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
SX-682 y nivolumab para el tratamiento del cáncer colorrectal metastásico o irresecable con mutación del RAS, el ensayo STOPTRAFFIC-1
